Furthermore, treatment with the FDA-approved drug trametinib (Tram), a potent MEK1/2 kinase inhibitor indicated for the treatment of melanoma with the BRAF V600E/K mutation57, greatly increased SIRT7 levels in A549 cells, MDA-231 cells, and 4T1 cells (Fig. 7j and Supplementary Fig. 13e). The gene discussed is BRAF; the disease is melanoma.